{"component": "clause", "props": {"groups": [{"size": 4, "samples": [{"hash": "lBkBB2aUcWL", "uri": "/contracts/lBkBB2aUcWL#initial-test", "label": "Participation Agreement (Ridgewood Energy T Fund LLC)", "score": 18.0, "published": true}, {"hash": "fcfIQNkqEEJ", "uri": "/contracts/fcfIQNkqEEJ#initial-test", "label": "Participation Agreement (Ridgewood Energy P Fund LLC)", "score": 18.0, "published": true}, {"hash": "6iyS1wx6F5p", "uri": "/contracts/6iyS1wx6F5p#initial-test", "label": "Participation Agreement (Ridgewood Energy O Fund LLC)", "score": 18.0, "published": true}], "snippet": "WELL -----------------", "snippet_links": [], "hash": "cd49f090dcbb9f23ee7bd9cffaeb479b", "id": 1}, {"size": 4, "samples": [{"hash": "g8jNWMRSNYr", "uri": "/contracts/g8jNWMRSNYr#initial-test", "label": "Collective Bargaining Agreement", "score": 23.3682409309, "published": true}, {"hash": "eROvc5q4yJD", "uri": "/contracts/eROvc5q4yJD#initial-test", "label": "Collective Bargaining Agreement", "score": 23.3682409309, "published": true}], "snippet": "The initial screen for all drugs except alcohol shall use an inununoassay. For alcohol the initial test may be the enzyme oxidation methodology. The following cutoff levels shall be used when first screening specimens to find whether they are negative or need to be tested further with the confirmation test. All levels equal to or exceeding the following shall be reported as positive: Alcohol 0.04% Amphetamines 1000 ng/ml Cannabinoids 50 ng/ml Cocaine 300 ng/ml Phencyclidine 25 ng/ml Methaqualone 300 ng/ml Opiates 2000 ng/ml Barbiturates 300 ng/ml Benzodiazepine 300 ng/ml Synthetic Narcotics: Methadone 300 ng/ml Propoxyphene 300 ng/\u2587\u2587 A positive finding will generate a confirmation test through the GC/MS (gas chromatography/mass spectrometry) method and the results will be kept confidential. A copy of any positive can be received by the employee by submitting his/her request in writing. As drug testing technology is constantly improving and state and federal laws governing said testing are changing almost as rapidly, the company may change the cut off levels without notice. The cut-off levels in effect for the GC/MS at the time of this printing are as follows: All information, interviews, reports, statements, memoranda and drug and alcohol test results may not be received in evidence, discovery, or disclosed without a written consent by the donor, except when compelled by a hearing officer or a court of competent jurisdiction, or where deemed appropriate by a professional or occupational licensing board in a related disciplinary proceeding, or in defense of a civil or administrative matter, or for the purpose of reviewing certification of employees.", "snippet_links": [{"key": "initial-screen", "type": "definition", "offset": [4, 18]}, {"key": "cutoff-levels", "type": "clause", "offset": [159, 172]}, {"key": "confirmation-test", "type": "definition", "offset": [290, 307]}, {"key": "all-levels", "type": "clause", "offset": [309, 319]}, {"key": "equal-to", "type": "definition", "offset": [320, 328]}, {"key": "gas-chromatography", "type": "definition", "offset": [714, 732]}, {"key": "mass-spectrometry", "type": "definition", "offset": [733, 750]}, {"key": "a-copy-of", "type": "clause", "offset": [802, 811]}, {"key": "employee-by", "type": "definition", "offset": [848, 859]}, {"key": "request-in-writing", "type": "clause", "offset": [879, 897]}, {"key": "testing-technology", "type": "clause", "offset": [907, 925]}, {"key": "laws-governing", "type": "clause", "offset": [972, 986]}, {"key": "the-company", "type": "definition", "offset": [1032, 1043]}, {"key": "without-notice", "type": "definition", "offset": [1074, 1088]}, {"key": "in-effect", "type": "definition", "offset": [1109, 1118]}, {"key": "at-the-time", "type": "clause", "offset": [1133, 1144]}, {"key": "all-information", "type": "clause", "offset": [1178, 1193]}, {"key": "alcohol-test-results", "type": "clause", "offset": [1251, 1271]}, {"key": "written-consent", "type": "definition", "offset": [1339, 1354]}, {"key": "hearing-officer", "type": "clause", "offset": [1396, 1411]}, {"key": "court-of-competent-jurisdiction", "type": "definition", "offset": [1417, 1448]}, {"key": "professional-or-occupational-licensing-board", "type": "definition", "offset": [1483, 1527]}, {"key": "disciplinary-proceeding", "type": "definition", "offset": [1541, 1564]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [1620, 1638]}, {"key": "certification-of-employees", "type": "clause", "offset": [1649, 1675]}], "hash": "fdeabcf4dd24d8328ccef7caf08849ff", "id": 2}, {"size": 4, "samples": [{"hash": "lBkBB2aUcWL", "uri": "/contracts/lBkBB2aUcWL#initial-test", "label": "Participation Agreement (Ridgewood Energy T Fund LLC)", "score": 18.0, "published": true}, {"hash": "6iyS1wx6F5p", "uri": "/contracts/6iyS1wx6F5p#initial-test", "label": "Participation Agreement (Ridgewood Energy O Fund LLC)", "score": 18.0, "published": true}], "snippet": "Well -----------------------------\n3.1 On or before May 30, 2007, Newfield shall commence actual drilling operations for the Eugene Island 346 (OCS-G-14482) No. 7 Well at an approximate surface \u2587\u2587\u2587 \u2587ottomhole location of 6,150' FSL and 900' FWL of Eugene Island 346 (\"Initial Test Well\"). The Initial Test Well will \u2587\u2587 \u2587\u2587\u2587lled in accordance with Newfield's AFE dated October 27, 2006, and shall be drilled to a proposed total depth of 12,890' TVD/MD, or to a depth sufficient to fully evaluate the \"GA-1\" Sand, whichever is lesser depth (\"Contract Depth\"). The \"GA-1\" Sand correlates to the shale interval which occurs at 10,550' MD (10,459' SSTVD) in the El 346, Anadarko Petroleum Corporation Well No. 1 ST-1 (OCS-G 14482).", "snippet_links": [{"key": "actual-drilling-operations", "type": "definition", "offset": [90, 116]}, {"key": "location-of", "type": "definition", "offset": [209, 220]}, {"key": "initial-test-well", "type": "clause", "offset": [268, 285]}, {"key": "in-accordance-with", "type": "definition", "offset": [327, 345]}, {"key": "a-proposed", "type": "clause", "offset": [409, 419]}, {"key": "contract-depth", "type": "definition", "offset": [539, 553]}, {"key": "anadarko-petroleum-corporation", "type": "clause", "offset": [664, 694]}], "hash": "62fbbf13c608e53f826d2ca3e08d4fab", "id": 3}, {"size": 2, "samples": [{"hash": "jJEgYxSKetS", "uri": "/contracts/jJEgYxSKetS#initial-test", "label": "Collective Bargaining Agreement", "score": 32.800791638, "published": true}, {"hash": "ju3aLzDAm6R", "uri": "/contracts/ju3aLzDAm6R#initial-test", "label": "Collective Bargaining Agreement", "score": 25.5311430527, "published": true}], "snippet": "The initial screen for all drugs shall use an immunoassay methodology except that the initial test for alcohol will be an enzyme oxidation methodology. The following cut-off levels, as established by Rule 59A of the Florida Administrative Code, shall be used when first screening specimens to determine whether they are positive or negative for the drugs or metabolites specifically listed below. (In the event that the following cut- off levels, as established by Rule 59A, are subsequently amended by legislation, the cut-off levels set forth below shall control.) All levels which meet or exceed the following shall be reported as positive and reported for confirmation testing: 5. Confirmation test \u2013 All specimens identified as positive on the initial test shall be confirmed using gas chromatography mass spectrometry (GC/MS) except that alcohol will be confirmed using gas chromatography (GC). All confirmations shall be done by quantitative analysis. Concentrations, which exceed the linear region of the standard curve, shall be documented in the laboratory record as \u201cgreater than highest standard curve value.\u201d The following confirmation cut-off levels, as established by Rule 59A of the Florida Administrative Code, shall be used when analyzing specimens to determine whether they are positive or negative for the drugs or metabolites specifically listed below. (In the event that the following confirmation cut-off levels, as established by Rule 59A, are subsequently amended by legislation, the confirmation cut-off levels set forth below shall", "snippet_links": [{"key": "initial-screen", "type": "definition", "offset": [4, 18]}, {"key": "florida-administrative-code", "type": "clause", "offset": [216, 243]}, {"key": "determine-whether", "type": "clause", "offset": [293, 310]}, {"key": "the-drugs", "type": "clause", "offset": [345, 354]}, {"key": "listed-below", "type": "clause", "offset": [383, 395]}, {"key": "in-the-event", "type": "clause", "offset": [398, 410]}, {"key": "all-levels", "type": "clause", "offset": [567, 577]}, {"key": "confirmation-testing", "type": "definition", "offset": [660, 680]}, {"key": "gas-chromatography", "type": "definition", "offset": [787, 805]}, {"key": "mass-spectrometry", "type": "definition", "offset": [806, 823]}, {"key": "quantitative-analysis", "type": "definition", "offset": [936, 957]}, {"key": "of-the-standard", "type": "clause", "offset": [1006, 1021]}], "hash": "6baa545018a6d1cd7b499c5102e4f849", "id": 4}, {"size": 2, "samples": [{"hash": "bjrvAK0GvZf", "uri": "/contracts/bjrvAK0GvZf#initial-test", "label": "Brownfield Cleanup Agreement", "score": 25.5532579869, "published": true}], "snippet": "an immunoassay screen to eliminate \"negative\" urine specimens from further consideration.", "snippet_links": [{"key": "further-consideration", "type": "definition", "offset": [67, 88]}], "hash": "df6541eef3c0ca0a2af69720acdaddd4", "id": 5}, {"size": 2, "samples": [{"hash": "3SWpey9UkMg", "uri": "/contracts/3SWpey9UkMg#initial-test", "label": "Participation Agreement (Ridgewood Energy P Fund LLC)", "score": 16.0, "published": true}], "snippet": "WELL ----------------- On or before August 31, 2006, Newfield shall commence actual drilling operations for the West Cameron 593 (OCS-G 02023) No. 5 Well at an approximate surface location of 3,850' FSL and 3,650' Newfield Exploration Company 363 N. Sam Houston Pkwy E. Suite 2020 Houston, Texas 77060 (281) \u258747-6000 Fax (281) 405-4242. WC 593 Farmout Agreement \u2587\u2587\u2587\u2587 \u2587, \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587 \u2587 FEL \u2587\u2587 \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587n 593 and bottom-hole location of 3,850' FSL and 3,650' FEL of West Cameron 593 (\"Initial Test Well\"). The Initial Test Well shall be drilled to an approximate depth of 12,700' MD/TVD, or a depth sufficient to test the \"K-1\" Sand Horizon as seen at 13,239' - 13,367' MD on that certain Induction Spherically Focused/Sonic Log for the OCS-G 02023 No. A-5 Well (API No. 17-702-40398-00), whichever depth is shallower (\"Contract Depth\"). The Initial Test Well, Additional Well or any Substitute Well (defined in Article II below) drilled under the terms of this Agreement, shall be drilled free of any cost and/or liability of any Kind or character to Farmors, and all risk, liability, costs or expenses incurred in connection with drilling, testing, completing, and associated tie-in of said well or wells and/or plugging or abandoning said well or wells shall be born\u2587 \u2587\u2587\u2587ely by Newfield, except as provided below. Newfield shall not be obligated to drill or commence drilling the Initial Test Well or any other well under the terms of this Agreement. If Newfield fails to commence drilling the Initial Test Well, Newfield will suffer no penalty other than the forfeiture of all rights under this Agreement.", "snippet_links": [{"key": "actual-drilling-operations", "type": "definition", "offset": [77, 103]}, {"key": "west-cameron", "type": "definition", "offset": [112, 124]}, {"key": "location-of", "type": "definition", "offset": [180, 191]}, {"key": "exploration-company", "type": "definition", "offset": [223, 242]}, {"key": "farmout-agreement", "type": "definition", "offset": [344, 361]}, {"key": "initial-test-well", "type": "clause", "offset": [482, 499]}, {"key": "contract-depth", "type": "definition", "offset": [817, 831]}, {"key": "additional-well", "type": "definition", "offset": [858, 873]}, {"key": "substitute-well", "type": "definition", "offset": [881, 896]}, {"key": "article-ii", "type": "definition", "offset": [909, 919]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [945, 968]}, {"key": "liability-of", "type": "clause", "offset": [1011, 1023]}, {"key": "all-risk", "type": "definition", "offset": [1062, 1070]}, {"key": "expenses-incurred", "type": "clause", "offset": [1092, 1109]}, {"key": "in-connection-with", "type": "clause", "offset": [1110, 1128]}, {"key": "well-or-wells", "type": "definition", "offset": [1190, 1203]}, {"key": "no-penalty", "type": "clause", "offset": [1534, 1544]}, {"key": "rights-under-this-agreement", "type": "clause", "offset": [1578, 1605]}], "hash": "6dc38fa195d9b4bee0c2d3cb014f3656", "id": 6}, {"size": 1, "samples": [{"hash": "9wv2uhxtCZJ", "uri": "/contracts/9wv2uhxtCZJ#initial-test", "label": "Collective Bargaining Agreement", "score": 24.0116358658, "published": true}], "snippet": "The initial test shall use an immunoassay which meets the requirements of the Food and Drug Administration for commercial distribution. The following initial cutoff levels shall be used when screening specimens to determine whether they are negative for these given drugs or classes of drugs. Initial Test Cutoff Levels (ng/ml) Marijuana metabolites 100 Cocaine metabolites 300 Opiate metabolites 300* Phencyclidine 25 Amphetamines 1,000 Alcohol .04 *25 ng/ml if immunoassay specific for free morphine. These cutoff levels are subject to change by the Department of Transportation as advances in technology or other considerations warrant identification of these substances at other concentrations.", "snippet_links": [{"key": "requirements-of-the", "type": "clause", "offset": [58, 77]}, {"key": "food-and-drug-administration", "type": "definition", "offset": [78, 106]}, {"key": "commercial-distribution", "type": "clause", "offset": [111, 134]}, {"key": "cutoff-levels", "type": "clause", "offset": [158, 171]}, {"key": "determine-whether", "type": "clause", "offset": [214, 231]}, {"key": "subject-to-change", "type": "clause", "offset": [527, 544]}, {"key": "department-of-transportation", "type": "definition", "offset": [552, 580]}, {"key": "other-considerations", "type": "definition", "offset": [610, 630]}], "hash": "049957290d6e3cb45fa5a9e4a23cbe43", "id": 7}, {"size": 1, "samples": [{"hash": "f4JXs5siGsV", "uri": "/contracts/f4JXs5siGsV#initial-test", "label": "Union Agreement", "score": 28.4554704225, "published": true}], "snippet": "The testing laboratory will use an immunoassay which has been approved for commercial use by the U.S. Food and Drug Administration. The laboratory will use the following cut-off levels for its initial test: Marijuana Metabolite 50 Ng/ml* Cocaine Metabolite 300 Ng/ml* Opiates 2,000 Ng/ml* Phencyclidine 25 Ng/ml* Amphetamine 1,000 Ng/ml*", "snippet_links": [{"key": "the-testing-laboratory", "type": "clause", "offset": [0, 22]}, {"key": "commercial-use", "type": "definition", "offset": [75, 89]}, {"key": "the-us", "type": "clause", "offset": [93, 100]}, {"key": "food-and-drug-administration", "type": "definition", "offset": [102, 130]}, {"key": "use-the-following", "type": "clause", "offset": [152, 169]}], "hash": "a9931d5a3cb3ff90b515495133767be0", "id": 8}, {"size": 1, "samples": [{"hash": "i5nkr3xKFHx", "uri": "/contracts/i5nkr3xKFHx#initial-test", "label": "Vendor Services Agreement (Endless Youth Products Inc)", "score": 16.0, "published": true}], "snippet": "Owners hereby grant Vendor the exclusive right to air the Infomercial for fifteen (15) days as an initial media test. Vendor shall commence this media test as soon as possible, but in no event later than March 28, 1998.", "snippet_links": [{"key": "right-to", "type": "definition", "offset": [41, 49]}, {"key": "vendor-shall", "type": "clause", "offset": [118, 130]}, {"key": "as-soon-as-possible", "type": "definition", "offset": [156, 175]}, {"key": "in-no-event", "type": "clause", "offset": [181, 192]}], "hash": "980bcaa47e4f71e863d1b48accb12904", "id": 9}, {"size": 1, "samples": [{"hash": "lkzIJxsRZpv", "uri": "/contracts/lkzIJxsRZpv#initial-test", "label": "Collective Bargaining Agreement", "score": 27.9160476181, "published": true}], "snippet": "The initial test screen for all drugs shall use in immunoassay except 15 that the initial test for alcohol shall be an enzyme oxidation methodology. The 16 following cutoff levels shall be used when first screening specimens to determine 17 whether they are positive or negative for these drugs or metabolites. All levels 18 equal to or exceeding the following shall be reported as positive: 19 Alcohol .04g% 20 Amphetamines 1000 mg/ml 21 Cannabinoids 100 mg/ml 22 Cocaine 300 mg/ml 23 Phencyclidine 25 mg/ml 24 Methaqualone 300 mg/ml 25 Opiates 300 mg/ml 26 Barbiturates 300 mg/ml 27 Benzodiazepines 300 mg/ml 28 Methadone 300 mg/ml 29 Propoxyphene 300 mg/ml 30 1 (c) Confirmation Test \u2013 All specimens identified as positive on the initial tests shall 2 be confirmed using a second test, a gas chromatography/mass spectrometry 3 (GC/MS) test, or an equivalent or more accurate scientifically accepted method 4 approved by the State or Federal government; except that alcohol will be confirmed 5 using gas chromatography. All confirmations shall be done by quantitative 7 specimens to determine whether they are positive or negative for these drugs or 8 metabolites. All levels equal to or exceeding the following shall be reported as 9 positive: 10 Alcohol .04g% 11 Amphetamines 500 mg/ml 12 Cannabinoids 15 mg/ml 13 Cocaine 150 mg/ml 14 Phencyclidine 25 mg/ml 15 Methaqualone 150 mg/ml 16 Opiates 300 mg/ml 17 Barbiturates 150 mg/ml 18 Benzodiazepines 150 mg/ml 19 Methadone 150 mg/ml 20 Propoxyphene 150 mg/ml", "snippet_links": [{"key": "cutoff-levels", "type": "clause", "offset": [166, 179]}, {"key": "to-determine", "type": "definition", "offset": [225, 237]}, {"key": "all-levels", "type": "clause", "offset": [311, 321]}, {"key": "equal-to", "type": "definition", "offset": [325, 333]}, {"key": "confirmation-test", "type": "definition", "offset": [669, 686]}, {"key": "initial-tests", "type": "definition", "offset": [733, 746]}, {"key": "second-test", "type": "clause", "offset": [776, 787]}, {"key": "gas-chromatography", "type": "definition", "offset": [791, 809]}, {"key": "mass-spectrometry", "type": "definition", "offset": [810, 827]}, {"key": "method-4", "type": "clause", "offset": [902, 910]}, {"key": "by-the-state", "type": "clause", "offset": [920, 932]}, {"key": "federal-government", "type": "definition", "offset": [936, 954]}, {"key": "determine-whether", "type": "clause", "offset": [1085, 1102]}], "hash": "b99333bee57854bfa3f10e393a9d52e5", "id": 10}], "next_curs": "ClUST2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjELEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhVpbml0aWFsLXRlc3QjMDAwMDAwMGEMogECZW4YACAA", "clause": {"size": 24, "children": [["routine-fitness-for-duty-testing", "Routine Fitness for Duty testing"], ["reasonable-suspicion-testing", "Reasonable Suspicion testing"], ["", ""], ["responsibilities-of-the-employee", "Responsibilities of the Employee"], ["grounds-for-discipline-or-termination", "Grounds for Discipline or Termination"]], "parents": [["successors-and-assigns", "Successors and Assigns"], ["general-terms-and-conditions", "General Terms and Conditions"], ["laboratories-procedures", "Laboratories\u2019 Procedures"], ["definitions", "Definitions"], ["severability", "SEVERABILITY"]], "title": "Initial Test", "id": "initial-test", "related": [["acceptance-tests", "Acceptance Tests", "Acceptance Tests"], ["acceptance-testing", "Acceptance Testing", "Acceptance Testing"], ["commercial-operation-date-testing-and-modifications", "Commercial Operation Date Testing and Modifications", "Commercial Operation Date Testing and Modifications"], ["refusal-to-test", "Refusal to Test", "Refusal to Test"], ["post-commercial-operation-date-testing-and-modifications", "Post-Commercial Operation Date Testing and Modifications", "Post-Commercial Operation Date Testing and Modifications"]], "related_snippets": [], "updated": "2025-07-07T12:37:53+00:00"}, "json": true, "cursor": ""}}